New Class of Cross-Neutralizing Antibodies Targeting Env V2-Apex

One of the greatest challenges in HIV vaccine development has been overcoming the virus’s ability to mutate rapidly and create diversity. An effective HIV vaccine must stimulate rare precursor B cells of multiple broadly neutralizing antibody (bNAb) lineages, which are crucial in developing immunity against the virus.^(1,2)

BEI Resources is supporting this research by offering new recombinant monoclonal antibodies (HRP-20364, HRP-20365, and HRP-20366) cloned from a purified single B cell isolated from a rhesus macaque infected with a chimeric simian-chimpanzee immunodeficiency virus (SCIV-CAM13K), which features an engineered gp120 envelope (Env) protein. This allows the antibodies to recognize epitopes in the variable loop 2 (V2) at the Env glycoprotein trimer apex.⁽³⁾

References:

1. Haynes, B. F., et al. “Strategies for HIV-1 Vaccines that Induce Broadly Neutralizing Antibodies.” Nat. Rev. Immunol. 23 (2023): 142-158. PubMed: 35962033.

2. Haynes, B.F., et al. “B-Cell–Lineage Immunogen Design in Vaccine Development with HIV-1 as a Case Study.” Nat. Biotechnol. 30 (2022):422-433. PubMed: 22565972.

3. Bibollet-Ruche, F., et al. “A Germline-Targeting Chimpanzee SIV Envelope Glycoprotein Elicits a New Class of V2-Apex Directed Cross-Neutralizing Antibodies.” mBio 14 (2023): e0337022. PubMed: 36629414.

Description / Alt Text: Colorized scanning electron micrograph of HIV-1 virus particles (blue) both budding and attached to the surface of Hut-78/human lymphocyte cells (red). Image captured at the NIAID Integrated Research Facility in Fort Detrick, Maryland. Credit: NIAID. (NIAID/CC BY 2.0)

Image Credit: Colorized SEM of HIV-1 virus particles both budding and attached to the surface of Hut-78/human lymphocyte cells. (NIAID/CC BY 2.0)